Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.82 |
| ▸ | RARA | P10276 | 6/20 | 0.54 |
| ▸ | RXRA | P19793 | 5/20 | 0.54 |
| ▸ | RARB | P10826 | 4/20 | 0.54 |
| ▸ | RARG | P13631 | 4/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | RXRB | P28702 | 2/20 | 0.54 |
| ▸ | RXRG | P48443 | 2/20 | 0.54 |
| ▸ | RORC | P51449 | 2/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | HTR2B | P41595 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | GMNN | O75496 | 2/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1765991 | 1.00 | MAPT (0.82) | MAPTALDH1A1SMN1; SMN2RARARXRA | |
| SCHEMBL7127846 | 0.90 | ALDH1A1 (1.00) | MAPTALDH1A1SMN1; SMN2RARARXRA | |
| SCHEMBL1718341 | 0.90 | ALDH1A1 (1.00) | MAPTALDH1A1SMN1; SMN2RARARXRA | |
| SCHEMBL1718339 | 0.90 | ALDH1A1 (1.00) | MAPTALDH1A1SMN1; SMN2RARARXRA | |
| SCHEMBL3500196 | 0.90 | ALDH1A1 (1.00) | MAPTALDH1A1SMN1; SMN2RARARXRA | |
| SCHEMBL23356521 | 0.90 | ALDH1A1 (1.00) | MAPTALDH1A1SMN1; SMN2RARARXRA | |
| SCHEMBL1498298 | 0.88 | MAPT (0.79) | MAPTALDH1A1SMN1; SMN2RARARXRA | |
| SCHEMBL13903879 | 0.87 | MAPT (0.77) | MAPTALDH1A1SMN1; SMN2RARARXRA | |
| SCHEMBL12786624 | 0.87 | MAPT (0.77) | MAPTALDH1A1SMN1; SMN2RARARXRA | |
| SCHEMBL5361434 | 0.87 | MAPT (0.77) | MAPTALDH1A1SMN1; SMN2RARARXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023168381-A1 | DEUTERATED RETINOIDAL COMPOUNDS AND SYNTHESIS AND USES THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-09-07 | — | — | WO | disclosed |
| EP-2512498-B1 | PEPTIDE PROTECTION AGAINST ULTRAVIOLET LIGHT TOXICITY | HELIX BIOMEDIX INC (US) | 2015-09-16 | — | — | EP | disclosed |
| US-8597902-B2 | Peptide protection against ultraviolet light toxicity | HELIX BIOMEDIX, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| EP-2512498-A2 | PEPTIDE PROTECTION AGAINST ULTRAVIOLET LIGHT TOXICITY | Helix Biomedix Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120225023-A1 | PEPTIDE PROTECTION AGAINST ULTRAVIOLET LIGHT TOXICITY | HELIX BIOMEDIX, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2011063090-A2 | PEPTIDE PROTECTION AGAINST ULTRAVIOLET LIGHT TOXICITY | HELIX BIOMEDIX INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-6586460-B1 | Administering heterocyclic ethers or sulfides to induce apoptosis, cell differentiation and as anticarcinogenic agents | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY | 2003-07-01 | — | — | US | disclosed |
| US-6355669-B1 | THERAPY FOR KIDNEY DISEASE USING BENZOIC ACID COMPOUND | EISAI CO., LTD. (JP) | 2002-03-12 | — | — | US | disclosed |
| EP-1025857-A1 | RETINOIC ACID AGONISTS AS PREVENTIVE AND THERAPEUTIC AGENTS FOR NEPHRITIS | Eisai Co., Ltd. (JP) | 2000-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225023-A1 | PEPTIDE PROTECTION AGAINST ULTRAVIOLET LIGHT TOXICITY | CHEK2, CHEK1, DDB1 | MAPT 3620/4885ALDH1A1 3791/4885SMN1; SMN2 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.